Kura Oncology (KURA) Cash from Operations (2010 - 2026)
Kura Oncology (KURA) reported Cash from Operations of 85854000.0 for Q1 2026, down 19.36% year-over-year from 106469321.69 in Q1 2025, and down 173.21% quarter-over-quarter from 117273000.0 in Q4 2025.
Kura Oncology (KURA) Cash from Operations (2010 - 2026) Analysis & Trends
Kura Oncology (KURA) has 17 years of Cash from Operations data on file, last reported at 85854000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 85854000.0, down 19.36% year-over-year; the trailing twelve-month figure through Mar 2026 was 77985000.0 (down 170.11% YoY), and the FY2025 annual result was 64058000.0, down 147.69% from the prior year.
- Cash from Operations declined to 85854000.0 in Q1 2026 per KURA's latest filing, from 117273000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 269131000.0 in Q4 2024 and troughed at 85854000.0 in Q1 2026.
- A 5-year average of 14734176.47 and a median of 32181000.0 in 2022 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 884.46% in 2024, then tumbled 85.61% in 2025.
- A 5-year view of Cash from Operations shows it stood at 26530000.0 in 2022, then decreased by 29.32% to 34308000.0 in 2023, then jumped by 884.46% to 269131000.0 in 2024, then plunged by 56.43% to 117273000.0 in 2025, then plunged by 173.21% to 85854000.0 in 2026.
- Business Quant data shows KURA's Cash from Operations at 85854000.0 in Q1 2026, 117273000.0 in Q4 2025, and 80627000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Kura Oncology | 883.44 Mn | 883.44 Mn | 18.00 Mn | -85.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.85 Mn |
| Mar 31, 2026 | -85.85 Mn |
| Dec 31, 2025 | 117.27 Mn |
| Dec 31, 2025 | 117.27 Mn |
| Sep 30, 2025 | -80.63 Mn |
| Sep 30, 2025 | -80.63 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Jun 30, 2025 | -28.78 Mn |
| Mar 31, 2025 | -71.93 Mn |
| Mar 31, 2025 | -71.93 Mn |
| Dec 31, 2024 | 269.13 Mn |
| Dec 31, 2024 | 269.13 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Sep 30, 2024 | -43.44 Mn |
| Jun 30, 2024 | -42.53 Mn |
| Jun 30, 2024 | -42.53 Mn |
| Mar 31, 2024 | -48.84 Mn |
| Mar 31, 2024 | -48.84 Mn |
| Dec 31, 2023 | -34.31 Mn |
| Dec 31, 2023 | -34.31 Mn |